August 15, 2007 -- China Biopharmaceuticals reported higher revenue and gross profit in its second quarter, though it reported a small loss for the period. The company is continuing to have difficulty with its year-old purchase of Enshi. China Biopharma has sued the former owner and the controlling shareholders of Enshi, seeking redress for what it regards as misrepresentations. On the other hand, the company’s other division, Erye, is performing well. Its revenues were up 31% over the year-ago period. More details...
